health corp expert
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Would be good to receive a report on the CES.
I'm very bullish on the market share they can achieve in the veterinary market. Penetrate the market before competitor enters the scene. I expext a $3 pps from Veterinary market alone.
And then human market. If ALR can offer a significant price reduction vs Dexcom, then watch out for spectacular fireworks.
Dexcom market cap is $43 billion.
Nuff said.
thank you Last one for doing the due diligence on SURG that I should have done prior to my comments
that's what I am afraid of when there is a reverse split-----they (surg) lost more than half their value and its been months since the up listing and still no improvement
hopefully ALRT will not have to reverse split. lets see a nice stock pps surge once a sales and distribution agreement is announced
Strong News. here is a link.
https://www.alrt.com/news/2021/10/21/alrt-releases-market-research
Agreed. This is strong. And suggests they are closing in on launching in this market. Appears they will dominate this market.
ALR Technologies Releases Select Results from Market Research on Diabetic Pet Industry; Market Demand High for Innovation
*GluCurve™ is the world’s first continuous glucose monitor (CGM) for diabetic dogs and cats
*GluCurve™ eliminates need for manual, costly and cumbersome “glucose curves” that are today’s standard of care
*2017 AVMA Report shows between 28,000-32,000 veterinary practices in U.S.
*97% of DVM survey respondents indicated they’d use a pet CGM system to diagnose and manage diabetic dogs and cats as soon as available
(October 21, 2021 -- Singapore) ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, is pleased to release select results from comprehensive market research conducted by the consulting firm SmartPharma, evaluating the current approach to diabetes diagnosis, glucose monitoring and insulin treatment in cats and dogs. The conclusions speak strongly about the market demand for innovation to modernize the arcane standard of care today, which ALRT interprets as highly favorable for introducing the GluCurve™ Pet CGM (continuous glucose monitoring) as a simple, accurate, reliable and pain-free system to treat the approximately 4.5 million diabetic dogs and cats worldwide.
GluCurve™ is the world’s first and only CGM for cats and dogs. Once applied to the pet, it automatically collects blood glucose readings every 5 minutes for up to 14 days. Over the course of 24 hours, 288 data points are transmitted via Bluetooth to the pet owner’s synchronized device and then to the ALRT portal where the data is analyzied and presented to the veterinarian to quickly and effortlessly facilitate optimal care.
“The market research included veterinarians from across the United States and ranged from small private practices to large corporate clinics, and the responses were simply fantastic, as they validated our contention that GluCurve™ would fill a large void in animal health care,” commented Sidney Chan, Chairman and CEO of ALR Technologies. “We have developed a turnkey system that eliminates pain points across the complete spectrum of diabetic pet care by bringing cutting edge technology into the companion animal market, a development vets, pets and pet owners can all appreciate. We look forward to the commercial launch of GluCurve™ as the survey indicated that the veterinary clinics will be making orders from the outset.”
Background
SmartPharma was commissioned for, amongst other things, the purpose of gaining preliminary product concept for the GluCurve™ Pet CGM, including the evaluation of attribute tradeoffs that could increase or decrease utility and use, as well as determining expected uptake and ongoing use of a novel CGM product designed specifically for DVM (Doctor of Veterinary Medicine) use in cats and dogs.
Typically, for each pet diagnosed with diabetes, a DVM will perform a “glucose curve,” an unpleasant day-long process involving multiple blood draws that must be repeated throughout the year to determine a proper insulin dosing regimen. Due to the inevitable stress of the process on the pets, blood glucose data is often skewed, driving costs higher and creating challenges with accurate insulin prescriptions.
Leveraging leading technology developed by ALRT for monitoring and managing diabetes in humans, including all requisite hardware and software to consistently deliver accurate results, GluCurve is redefining the standard of care in diabetic companion animals by providing precise and effortless glucose readings while the pet is in the comfort of their home. The system is expected to come with the added benefit of being competitively priced below the average cost of in-clinic glucose curves or using a human CGM off-label.
Brian Zorn, Pharm.D., co-founder and managing partner, SmartPharma LLC commented, “In over a decade of conducting market research on new products with clinicians of all types, the veterinarian ratings on likelihood to use this product were among the highest we have ever seen.”
4 Key Takeaways from Market Research:
Large market opportunity
a. On average, DVMs interviewed had 43 dogs and cats under care for diabetes in past 12 months. b. DVM participants evaluate ~15-20 dogs and cats per month for diabetes, with a median of new diagnoses of 2 dogs and 1 cat monthly
DVMs desperate for reliable data a. 40% of DVMs surveyed have tried FreeStyle Libre (a human CGM) on a dog or cat b. FreeStyle Libre not approved or designed for animals
c. Despite associated risks, perception is that data from FreeStyle Libre is still better than in-clinic glucose curves
Multiple factors driving high interest from DVMs for GluCurve
a. Better for pet
b. Higher quality data
c. Easier to use (CGM application, data collection, analysis)
d. Affordable – 80% of DVMs surveyed said proposed price was “reasonable” or “too low”
DVMS surveyed had overwhelmingly favorable impression of GluCurve product
a. 97% of respondents indicated they would use GluCurve
b. DVMs expected to order, on average, 5 units once commercially available, with those managing larger diabetic pet populations indicating orders in larger quantities
“Our position from the beginning has been that a comprehensive pet CGM product has blockbuster potential,” commented Joe Stern, Head of Animal Health at ALR Technologies. “The market research demonstrates that it is not just us saying that; it is the DVMs. Between their reported 97% adoption rate and the size of the market, we are very optimistic about the potential revenue and value the GluCurve™ Pet CGM will bring to ALRT and our shareholders.”
About SmartPharma LLC
SmartPharma is a specialized pharmaceutical and device consulting firm that works with products in all phases of development and clients throughout the world. They specialize in custom market research studies, market and product assessments and forecasts, commercial strategy, and support for new product launches. www.smartpharmainc.com
think hundreds of millions for the size of the deal. The two most likely in my mind are Merck and Boehringer Ingelheim. Each are mega Global Pharma companies. Merck sales last year were nearly $50 billion and Boehringer nearly $25 billion and each are near the top in the Animal Health market.
A several hundred million dollar deal is a small thing for these two giants. They have animal market insulin sales. This market should more than double with the use of the ALRT system. And bringing the synergistic sales increase for insulin.
This must be significant. The two most likely pharma companies would be the two that provide insulin to the pet diabetes marketplace. MERCK and BOEHRINGER INGELHEIM. Each of these two companies has global distribution and sales.
This is significant in many ways but for these two MEGA companies to take a liking to ALRT shows the credibility and value of the ALRT Diabetes Solution. The process for the veterinarian will become much much easier and as such should grow the number of pets on insulin substantially.
This could represent hundreds of millions in annual sales for either Merck or Boehringer Ingelheim.
news out. go to website
news out. go to website
700,000 with Diabetes in Singapore. This is the number to focus on not the membership in the association. Don't forget the main hospital with ties to Ministry of Health is conducting a pilot. The synergies of both should bring about rapid utilization.
The credibility of this development will help with signing on groups in the US, Canada, Korea, Japan, and SE asia.
Key takeaways from this news:
---this is not a pilot....it is revenue
---Mr Tiwari's quote " new dimension" "add reliability and resilience"
---the potential number is much more than the membership number
---700,000 in Singapore with Diabetes
---Singapore Health is very influential with most SE asian countries
agreed. The drop in insulin price for Medicare creates a huge opportunity. I'm betting every insulin manufacturer is searching for ways to gain market share like never before. I'm also thinking one of the major insulin manufacturers will end up partnering with ALRT and market the ALRT Diabetes Solution along with their insulin. No additional cost and much,much more benefit. Now we just need the insulin manufacturers to become aware of, and understand the benefit of the ALRT Diabetes Solution. talk about the best of market differentiation...the manufacturer that teams with ALRT will definitely have a significant advantage with the ALRT insulin dose adjustment benefit. any doctor would want this available. I feel the fun is beginning.
Lastone; the description of ALRT is excellent under the "about" Maybe this should be placed on the description in INVESTORS HUB.
the ALRT press release regarding TeleHealth is critical for the diabetes care community and hopefully those health providers who care for diabetics will see it. Diabetic patients are high risk due to the many co-morbidities they have and immuno-suppressed. The opportunity for the care that the ALRT Diabetes Solution allows is far better than even an in-clinic appointment can provide in many cases.....they have the history of glucose readings AND the A1c prediction as well as insulin adjustment....and keeping the patient from risky exposure in the medical clinic. This service should become standard operating procedure in healthcare and the ALRT solution can identify when a patient would have need to make that trip to the office. I've worked in this area of care for many years. I hope that the healthcare industry will soon recognize ALRT----seems that few in that industry are aware of them yet. It's for the benefit of the providers, the patients and the healthcare payers, and will reduce overall costs.
Check out their Twitter postings
ALRTechnologies
@alrtechnologies
Provides easy to follow information that gives good understanding of their system and the benefits it provides. Differentiated in high value ways.
This will gain traction in Health Industry.....they are just not known yet.
LastOne. I concur with what you say here. I found it amusing how so many reacted the way they did. Yes it was old news and there is nothing negative about it. I picked up more shares as well.
thank you LastOne. I'll be joining
exactly. it only takes bit of brain to know that this PPS will not go up until announcements of contracts that bring certainty to revenue. The price now, whether. .00, .02, .04 or .09 means nothing to me.
So glad the whiners keep telling us there is nothing happening. I wouldn't know that without their brilliant insight. I swear this TJ guy and the McVee guy are the same person.....at least the same personality defects.
You either think there is progress being made or not. Once a contract is signed we'll hear about it. Once that happens, I would expect others to follow. I've been in this longer than most anyone. I'm certain their product will bring benefit to the industry. For those who are not familiar, when the EMRs and EHRs were trying to gain a foothold it took a long time for acceptance and then the govt stepped in and demanded the industry adopt and utilize. The ALRT platform is similar.......it's n incredible platform with data analyses that brings patient management to the appropriate level. This LVGO company product does not do this. nd because the ALRT system is provider centric it requires a much different timeline to bring about acceptance to change and adoption.
love it.......good one DS
nice try in defending your buddy. The majority of his messages are derogatory, and some have been clearly racist. We all question company decisions and lack of progress. That's definitely part of the investing analyses process. It's the continued multi-daily belligerent comments with no basis and certainly no understanding of the issues that the company with FDA cleared technology has to hurdle and weave through. It is painful to watch this guy do this to himself every day.
I'll not make excuses for ALRT but I've been in this space for years and change comes so slowly. LVGO is different because it's patient centric, fewer barriers to entry. But I'm glad ALRT is not patient centric. IMO ALRT is set for long term growth whereas LVGO has limited growth potential in the diabetes segment. In two years I estimate ALRT will have 5 times more diabetes patients on their platform than LVGO will have.
No way did ALRT have that last PR put out to impact PPS IMO. They are not pump & dump.
Those who truly follow this company know that well.
Many on this message board treat ALRT like typical penny stock. They re not ht IMO. They re true growth company on the cusp of breakout. Their products are real and recognized by the FD as such. Their primary target market is large and in much need of the care management that the ALRT service can bring.
So the "nothing burger" guy is back at it. Doubt he owns any stock. Likely just a guy who is out for some type of self punishment. But gets to read his own BS and that gets him some relief. I wish him well.
the PR is good stuff. I'm positive it was never intended nor expected to influence PPS. Only to set the stage for longer strategy and to begin the education process on the differences.
My experience with this type of PR is that it's part of a broader strategy with carefully planned timing. It would usually precede some more important news. I'm thinking that some fundamental market involvement news could be coming out soon. We'll see.
But, talking about bias, many of the comments on this board are based on negative bias against ALRT and not facts. Read carefully how the ALRT diabetes solution works and how the pricing is bundled. Read carefully how the solution is directed to large health plans or large govt plans. Provides important services that LVGO doesn't come close to. LVGO is dependent on the patient which has proven to not work well.
Why has it taken ALRT such time to get contracts for use? Good question but I focus on where they are now, and not the past. Change comes slowly to health care. The health providers resist change. Often does take years.
I now believe they have "Arrived"
For the Tony guy to keep his BS going, have to wonder why he's not sold out.
Strange.
it's likely great strategy. My experience with this type of PR is that it's part of a broader strategy with carefully planned timing. It would usually precede some more important news. I'm thinking that some fundamental market involvement news could be coming out soon. We'll see.
But, talking about bias, many of the comments on this board are based on negative bias against ALRT and not facts. Read carefully how the ALRT diabetes solution works and how the pricing is bundled. Read carefully how the solution is directed to large health plans or large govt plans. Provides important services that LVGO doesn't come close to. LVGO is dependent on the patient which has proven to not work well.
Why has it taken ALRT such time to get contracts for use? Good question but I focus on where they are now, and not the past. Change comes slowly to health care. The health providers resist change. Often does take years.
I now believe they have "Arrived"
This is good. Shows the important attributes that ALRT has that LVGO does not.
Livongo Thinks ALR Technologies (OTC: ALRT) Isnt a Competitor - They're Wrong!
MENAFN - Baystreet.ca) When Livongo (NASDAQ: LVGO) completed its IPO in July, it demonstrated that Wall Street is once again hungry for digital-health startups. The Silicon Valley developer of devices and software for managing diabetes upsized its pricing from an initial range of $20-$23 per share to finally list at $28, raising over $355 million and earning a valuation around $2.5 billion.
After blistering ahead to as high as $45.68 on the fifth day of trading, the wheels started coming off and Livongo has since skidded back to its initial pricing range and headed below $20. The culprits in the plunge for the health-monitoring device maker were a mixed earnings report and soft guidance.
During Q2, Livongo reported revenue surging 156% from the year prior quarter to $40.9 million. That beat the $39.8 million Wall Street expected. GAAP net loss for the quarter came in at$14.2 million , or $0.76 per share, far more than the consensus for a loss of $0.60 per share.
An upstart losing money certainly isn't news. After all, it is the opportunity that Livongo is addressing that has Wall Street's attention. As LVGO CEO Zane Burke commented during thequarterly call , the company has "barely scratched the surface," with less than 1% of the addressable market in the U.S.
That also means that there is a lot of market out there for others to join the mix and capture share.
Livongo's Competition
Livongo is a consumer-centric company addressing chronic diseases, starting with diabetes and moving into hypertension, weight management, pre-diabetes and behavioral health. Members using Livongo for Diabetes receive a smart, cellular-connected meter, automatically-delivered testing materials, real-time coaching and monitoring 24 hours a day, seven days a week, 365 days a year. When members track their blood glucose, they receive a personalized message about what to do that very moment, which Livongo calls a "health nudge."
According toLivongo's prospectusfiled with the SEC, "Our competitors include both enterprise companies who are focused on or may enter the healthcare industry, including initiatives and partnerships launched by these large companies, and from private companies that offer point solutions for a single chronic condition. These companies, which may offer their solutions at lower prices, are continuing to develop additional products and becoming more sophisticated and effective."
Reading the prospectus provides all the legal boilerplate stuff about why Livongo could fail. This, of course, includes competition. The odd thing is, though, that Livongo doesn't mention "public" companies. In fact, all the brands actually named - Virta Health Corp., Omada Health, Inc., Glooko, Inc., Hello Heart Inc., Lyra Health, Inc., Onduo LLC, and Ginger.io, Inc. - are private entities.
No public companies are competition?
While much smaller in valuation with a $10.5 million market capitalization, ALRT certainly thinks it is competition. The Virginia-based company has developed the ALRT Diabetes Solution. The technology is a comprehensive approach to diabetes care that includes:
- an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices;
- a patent pending Predictive A1C to track treatment success between lab reports;
- FDA-cleared Insulin Dosing Adjustment that suggests insulin dosing changes per evidence-based guidelines to optimize insulin therapy;
- performance tracking to ensure best practices are followed;
- automated patient management; and
- a Health Care Provider (HCP)-centric system, which is novel compared to Livongo and similar platforms that are consumer-centric
As with Livongo, ALRT is initially focused on diabetes with intentions to expand into other chronic diseases anchored by verifiable data.
Certainly sounds like potential competition.
Why Diabetes First?
Livongo and ALRT are both tackling diabetes first because of the immense size of the opportunity. Owing largely to aging and overweight populations, diabetes has reached epidemic proportions worldwide. According to the World Health Organization, the number of people with diabetes has risen from 108 million in 1980 to422 millionin 2014. If current trends do not change, the figure is expected to rise to 642 million people living with diabetes worldwide by 2040.
In the U.S., data from theAmerican Diabetes Associationshows 30 million people have diabetes and 84 million have prediabetes. That's 1 in 3 Americans coping with the disease or serious threat of it. The total cost of diagnosed diabetes is staggering at $327 billion annually ($237 billion in direct medical costs and $90 billion in reduced productivity), putting serious drag on an already strained healthcare system.
On average, medical expenditures for an American with diabetes is $16,752 per year, of which $9,601 is attributed to the disease.
Taking a broader view, the global cost of diabetes was estimated at a whopping$825 billionannually in 2016.
Livongo vs. ALRT
In fairness, an analyst would likely not make an apples-to-apples comparison between Livongo and ALR Technologies. Without question, Livongo is much larger, better capitalized, generating growing revenues and has a diverse product offering. Livongo is now a whole-health company, whereas ALRT is a comprehensive diabetes management company that includes medical treatment tools.
However, there is certainly a case to be made that ALRT is in a good position with its technology, as it is more treatment-centric for HCPs and insurers, and less of a consumer app than Livongo's broad spectrum technology.
ALRT's approach to delivering diabetes treatment has global application rather than just the U.S. consumer market. This will allow the company to grow expeditiously with the right worldwide strategic partners. According to ALRT management, their system is being evaluated and launched in several countries.
The Differentiators
On the surface, there are similarities in the systems of Livongo and ALRT in that they both aim to improve patient outcomes. How they achieve this, though, is quite different.
As mentioned, Livongo is consumer-centric. Members receive Livongo-branded blood glucose meters as part of a kit that includes Livongo-branded test strips, lancets, lancing device and case. In other words, all the medical devices diabetics use regularly. Additional strips are provided at no cost when needed. The system is a closed, proprietary system that doesn't operate on iOS or Android.
When members test their blood glucose, the Livongo meter automatically uploads the data to the user's online account and makes a recommendation what to do at that moment. For instance, the "nudge" might indicate that the person's blood glucose level is typically higher at that particular time of the day and ask if they would like to reach out to a "coach." If the glucose level is out of range, the coach will provide advice about how to get back into range. Authorized parties (relative, friend, etc.) can also be sent text messages about readings to provide oversight and keep up to speed with glucose levels.
ALRT is HCP-centric, agnostic and proactive. It operates on iOS, Android, Windows and MacOS systems and includes a branded meter. Just like the Livongo system, ALRT's technology collects all the blood glucose data, uploads it to a secure account and ships additional test strips as required. The data is aggregated to a Predictive A1C value for a comprehensive view of the treatment plan and patient adherence to the plan, with the data available (and messaged) to authorized people.
A tremendous difference between ALRT and Livongo is what happens next.
Livongo members need to take the initiative and reach out to a coach if readings are outside the pre-defined acceptable range. ALRT's system initiates the dialogue with all authorized parties and also includes treatment adjustment suggestions for the HCP when appropriate.
By contacting the HCP, the ALRT system drills down on what is called " clinical inertia " and the problems associated with it. Clinical inertia is defined as a failure to intensify therapy appropriately when treatment goals have not been met. With diabetes, failure to respond to higher A1C (hemoglobin A1c - an average level of blood sugar, also called HbA1c) with treatment intensification puts the patient at risk for complications and diabetes-associated co-morbidities.
Common complications of diabetes include cardiovascular disease, nerve damage, renal problems and blindness, to name a few.
How Important is Clinical Inertia? Check This Out
A team atCleveland Clinicexamined historical electronic medical record data of more than 7,300 patients with type 2 diabetes and concluded that there is a pervasiveness of clinical inertia for the management of type 2 diabetes in real-world clinical practice settings.
The selected patients had an A1C value of > 7 percent on a stable regimen of two oral anti-diabetic agents for at least 6 months (from 2005-2016). The median time to treatment intensification after HbA1C was above target, was longer than one year. For patients with an A1C of > 9 percent, therapy was not intensified in 44 percent of patients.
According to lead study author Dr Kevin Pantalone of Cleveland Clinic's Endocrinology & Metabolism Institute, "Short of a patient reporting non-adherence to their existing regimen of diabetes therapies, it is hard to imagine a reason why treatment intensification was not observed more frequently, when indicated, particularly in patients with an A1C > 9 percent. In general, if intensification does not occur, the A1C can be expected to stay the same or get worse, it is not magically going to get better." (emphasis added)
In short, the ALRT system aggressively initiates intervention by notifying the HCP of out of range results and does not directly relying on the patient. In Canada, some pharmacists are reimbursed for titrating medications and the ALRT Diabetes Solution provides the notifications and audit trail needed for achieving best practice results. This market is an interesting one for ALRT and could have applications throughout the world where clinical inertia can be addressed at a local level.
ALRT Diabetes Solution Features
Predicative A1C
Predictive A1C is a patent-pending unique feature for monitoring the effectiveness of care plans. This technology utilizes data diagnostics to compare targeted A1C with indicated results. Weekly patient blood glucose data is evaluated, and HCPs are notified as needed for care plan review when blood glucose values exceed parameters set by the HCPs.
Predictive A1C is a feature of the ALRT Diabetes Solution designed to assist HCPs in addressing clinical inertia in diabetes care.
Insulin Dose Adjustment
Insulin Dose Adjustment is an FDA cleared feature that makes optimal insulin adjustment suggestions to HCPs based on dosing guidelines, when required.
ALRT's system focuses on therapy optimization and insulin manufacturers could be interested in working with ALRT because of the impact this approach has on pharmaceutical sales volumes. The insulin market is dominated by three major players - Eli Lilly (NYSE: LLY), Sanofi (NASDAQ: SNY) and Novo Nordisk (NYSE: NVO). Being part of a complete care system that focuses on timely intensification could help a participating manufacturer increase its portion of the overall insulin market.
There are 10 more pharmaceutical companies of non-insulin diabetes therapies that also may be interested in working with ALRT to expand use of this functionality.
Leveraging Clinical Data
While remaining complaint with all HIPAA guidelines, ALRT is also in the clinical data business to create a new standard of care for diabetes and ultimately other chronic diseases. The data collection is valuable to payers when addressing a significant problem, patient non-adherence. Data-driven best practices are key to containing exploding complication rates and co-morbidity costs.
Tracking
A payer (government-sponsored medical care, private insurance company, employer-paid self-insured plan, etc.) is incentivized to use the ALRT system because they can track patient adherence to best practices by both the HCPs and patients.
Livongo does not provide the data analysis functionality that ALRT does, which inefficiently puts the burden on HCPs to analyze.
Conclusion
According to ALRT, it expects to bring its product to market at a substantial discount (>50%) compared to Livongo. With all the additional medical treatment features, clinical data, and qualities that provide meaningful value to payers, it's hard to believe that Livongo didn't recognize ALR Technologies as a competitor in its primary field - diabetes - because it certainly looks like it could be
sell out. I'll buy it all. Then go away. What do you have, one million.
You make up stuff the same way Adam Schiff does.
what is disturbing are the comments made by those who clearly do not have knowledge or understanding of what they speak to. and they monopolize the board with tired BS comments. But, I'm good......I'm continue to buy and add to my holdings. and those BS comments will not have any impact on PPS. I just don't appreciate those who disseminate disinformation.
Mr. TJ---I no longer find your rantings comical. They re pure nonsense and as such I feel you rant just to see reaction and to feel something cool about yourself.
Regarding the CEO. I know of no other CEO who would continue to support a company that has been through the years of trials that this CEO has. His support in financing is now in excess of $20 million. and given his wife and family are by far the majority debt holders they could bankrupt the company but they choose to support all of us little shareholders and keep us in the hunt.
about the timing-----yes, it's frustrating but I've been involved in medical devices/biotech and medical technology for 3 decades and know well the time it can take to achieve market use startup.
Credibility: how bout achieving 2 FDA clearances. thats credibility. Especially given the nature of the product...........its no generic drug where the predicates are clear. and the differentiation that the ALRT Diabetes Solution offers is not just being different, it's being different in very important and valuable ways. A1c predictor and insulin dose adjustment are each such an important addition.
Now about PRs. Mr. TJ......you were begging for PRs. You just got 2 of them and you complain. Most PRs are not expected to impact PPS. These were important, especially the addition of CGMs. This adds another fifteen % to overall potential. No fluff here. I'm waiting for news releases, not PRs. News releases will be about signed agreements with user/payers. I expect some nice PPS action by Thanksgiving.
I think your buddy complained about Mr. Chan's salary. Do you really think he's receiving any of that. I think not......I'm sure it's being accrued. He would be taking money from himself to pay himself.
Meaningless rants are nothing but fluff....... good nickname for those who do it.
so predictable and expected from you and your buddy. So if the two of you sell all your holdings then you two won't have the heartburn a we won't have to listen/read your BS crying.
I wouldn't expect market reaction to these last two PR releases. In my opinion they show the new features that potential customers (primarily self insured plans a countries with govt paid plans will see as added benefit.
IMO, market reaction will take place only with the news of customers signing on to use the platform. IMO, that market reaction will be significant, there will be PPS gaps. tenX, twentyX are realistic.
this sentence is powerful:
"We will be offering the complete package bundled with and at the cost of very competitively priced blood glucose testing supplies"
So it's like buying a new car at a discount and being provided a high quality garage with it free of charge.
I don't see any roadblocks for providers/payers. Important additional benefits at no extra charge. Great fit for self insured and govt paid programs
LastOne..all this makes sense to me. BTW--26 million in the US with diabetes
Jamma , the email shown in press releases is info@alrt.com. So I'm sure Mr. Chan would receive it if it's addressed to him.
nice to see the two CCs have each other to smooch to. CC equals of course...clueless clowns
I appreciate your message......I'm confident we'll see the company succeed. I've had 40 years in healthcare and pharma. I've been involved with diabetes management for years. I know well the benefits that the ALRT system brings to diabetes care. Between me and close friends we own nearly 20 million shares of ALRT. We're holding and have been buying more this summer. I'm getting old but I expect significant PPS over the next 6 months. $1 to $2 by end of year..IMO
LOL, I agree with you about AJ.----he adds humor. and I do believe he has an objective with his continuous messages. whereas the McPhee doesn't seem to have a clue.....probably a youngster, inexperienced.
HA HA----hook line and sinker---you've shown just what you are.
goodbye
must be nice that you and your twin AJ have so much idle time to mutter such nonsense multiple times a day. proud of yourself?
hahaha ---- you really are so funny.
well stated LastOne
so you must think that the company is purposely not putting out news. Crying out "where is the PR" every day is just like a kid saying "are we there yet" several times during a family rod trip. Does it help you get there sooner? I think not. Thankfully I find your daily agitation somewhat comical. I'm sure that ALRT will put out news once they have a deal completed.